药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Mecasermin
Gremubamab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Gremubamab.
Mecasermin
Pateclizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Pateclizumab.
Mecasermin
Dalantercept
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dalantercept.
Mecasermin
Margetuximab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Margetuximab.
Mecasermin
Trastuzumab deruxtecan
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Trastuzumab deruxtecan.
Mecasermin
Opicinumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Opicinumab.
Mecasermin
Pamrevlumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Pamrevlumab.
Mecasermin
Bermekimab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bermekimab.
Mecasermin
Refanezumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Refanezumab.
Mecasermin
Bevacizumab zirconium Zr-89
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bevacizumab zirconium Zr-89.
Mecasermin
Emactuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Emactuzumab.
Mecasermin
Parsatuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Parsatuzumab.
Mecasermin
Vobarilizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Vobarilizumab.
Mecasermin
Lintuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lintuzumab.
Mecasermin
Xentuzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Xentuzumab.
Mecasermin
Brolucizumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Brolucizumab.
Mecasermin
Codrituzumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Codrituzumab.
Mecasermin
Icrucumab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Icrucumab.
Mecasermin
Isatuximab
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Isatuximab.
Mecasermin
Anetumab ravtansine
The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Anetumab ravtansine.